Cellectis S.A. - American Depositary Shares —— 财务报表 (NASDAQ:CLLS) | MetaTrader

展开完整图表

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

新闻

Jefferies 以买入评级接手 Cellectis 股票分析

Jefferies assumes coverage on Cellectis stock with Buy rating

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Clear Street 以CAR-T潜力为由给Cellectis股票评级为"买入"

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)

Allogene股价在有利仲裁裁决重申疗法权利后上涨

仲裁裁决重申Allogene对癌症疗法的控制权

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights

仲裁裁决部分终止Cellectis-Servier许可协议